Concord Biotech — 360° view

Concord Biotech, a company in the Pharmaceuticals industry, reported revenue of ₹312 crore and net profit of ₹76 crore for the September 2026 quarter.

Concord Biotech (NSE: CONCORDBIO) closed at ₹548.20 on 20 Nov 2026, down 23.9% over the past year. Its market capitalisation is ₹11,470 crore and it trades at 38.6 times earnings.

Share price
₹548.20 (20 Nov 2026)
Market cap
₹11,470 Cr (20 Nov 2026)
P/E
38.60 (20 Nov 2026)
Revenue
₹312 Cr (September 2026 quarter)
Net profit
₹76 Cr (September 2026 quarter)
ROCE
17.4% (FY26)
ROE
13.0% (FY26)
Book value
₹99.7 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹807.50 / ₹493.50 (20 Nov 2026)
1-year return
-23.9% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: CONCORDBIO

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.